找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Anticoagulation Therapy; Joe F. Lau,Geoffrey D. Barnes,Michael B. Streiff Book 2018 Springer International Publishing AG, part of Springer

[复制链接]
楼主: 烹饪
发表于 2025-3-25 06:39:47 | 显示全部楼层
https://doi.org/10.1007/978-3-662-62034-2lex. However, delayed diagnosis and inadequate or inappropriate treatment can lead to life- and limb-threatening outcomes. This chapter will describe the syndrome of HIT (and HITT—heparin-induced thrombocytopenia with thrombosis) as it is now known, including its history, pathophysiology, diagnostic
发表于 2025-3-25 11:09:25 | 显示全部楼层
Introduction,uman anatomy in health and disease led to greater understanding of the pathophysiology of thrombotic disease and the first treatments for it. Modern approaches to treatment of arterial and venous thromboembolism emerged in the late 19th and 20th centuries with the identification of acetylsalicylic a
发表于 2025-3-25 13:27:20 | 显示全部楼层
Warfaringh very effective for prevention and treatment of venous and arterial thromboembolism, warfarin has a narrow therapeutic index, many drug, disease, and dietary interactions, and requires frequent monitoring and dose adjustments (Ageno et al., Chest 141(2 Suppl):e44S–88S, 2012; Holbrook et al., Chest
发表于 2025-3-25 18:06:13 | 显示全部楼层
Unfractionated Heparin and Low-Molecular-Weight Heparindications, including the treatment of venous thromboembolism, thromboprophylaxis, and acute coronary syndromes. In this chapter, we review the evidence-based recommendations and pharmacology of both UFH and LMWH with a detailed description of their mechanisms of action, pharmacokinetics, and pharmac
发表于 2025-3-25 19:59:57 | 显示全部楼层
Parenteral Anticoagulants: Direct Thrombin Inhibitors and Pentasaccharideses. These include a non-specific mechanism of action, high degree of non-specific binding to plasma components, unpredictable pharmacokinetics and pharmacodynamics, considerable inter- and intra-patient variability, a narrow therapeutic index, need for routine monitoring, and the potential for adver
发表于 2025-3-26 03:38:56 | 显示全部楼层
Direct Oral Anticoagulantsan—have been approved for prevention of stroke in non-valvular atrial fibrillation and treatment of venous thromboembolism (VTE). All except edoxaban also are approved to prevent VTE in hip and knee replacement surgery. In the atrial fibrillation trials, the DOACs were non-inferior to warfarin dose-
发表于 2025-3-26 06:35:37 | 显示全部楼层
Anticoagulation Reversal such therapy have to be outweighed against the risks of major bleeding complications. Such risk varies according to age and has been reported to be as low as 2–3% per year in adults to as high as 6–8% per year in the elderly. Reversal strategies are important both for the treatment of such major he
发表于 2025-3-26 11:49:28 | 显示全部楼层
Transitioning Between Anticoagulantsrsible, does not require monitoring, and can be used in patients with end-stage renal disease and moderate-severe liver dysfunction—is not available to date. Currently, the differences in the pharmacokinetic and pharmacodynamic properties of each agent allow for a unique, individualized anticoagulat
发表于 2025-3-26 13:46:52 | 显示全部楼层
The Anticoagulation Clinicfe and effective anticoagulation relies upon an organized system of care delivery, close collaboration between healthcare teams, effective communication with patients, and anticoagulation management performed by healthcare professionals with specialized training. The anticoagulation management servi
发表于 2025-3-26 19:35:54 | 显示全部楼层
Perioperative Management of Anticoagulantstients scheduled for surgery is challenging, as the interruption of therapy may increase the risk of thromboembolism, and continuation may predispose patients to increased peri- and intraoperative bleeding risks. It is therefore crucial to conduct an individualized and thorough periprocedural assess
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-17 13:23
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表